Toolkit aims to break the silence around inherited cancer genes
NCT ID NCT04428736
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a 'Disclosure Toolkit'—including a family letter, a chatbot, and a website—helps people with BRCA1 or BRCA2 mutations share their genetic test results with at-risk relatives. Researchers enrolled 52 participants to see if the toolkit improves communication and encourages relatives to get tested. The goal is to find better ways to spread life-saving genetic information within families.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Disclosure Toolkit (family letter, chatbot, website)
What this could lead to
If successful, this toolkit could help more at-risk relatives learn about their genetic risks and get tested, potentially preventing cancer through early detection.
What could go wrong
This is a small, completed study with only 52 participants, so results may not apply to everyone. The toolkit's impact on actual testing rates is uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA1 MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States